Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2. (2022)
Attributed to:
Impact of network-structured populations on evolution
funded by
EPSRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1186/s12879-022-07239-z
PubMed Identifier: 35307024
Publication URI: http://europepmc.org/abstract/MED/35307024
Type: Journal Article/Review
Volume: 22
Parent Publication: BMC infectious diseases
Issue: 1
ISSN: 1471-2334